# Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus

> **NCT05417880** · PHASE3 · UNKNOWN · sponsor: **Scotmann Pharmaceuticals** · enrollment: 340 (estimated)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Oral Hypoglycemic Agents,Oral
- **DRUG:** Voreta
- **DRUG:** Voreta plus SunnyD PRO

## Key facts

- **NCT ID:** NCT05417880
- **Lead sponsor:** Scotmann Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08
- **Primary completion:** 2023-02
- **Final completion:** 2023-06
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2022-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05417880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05417880, "Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05417880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*